Ovarian Carcinoma Surveillance Counterpoint: USA
Reference17 articles.
1. Markman M. Follow-up of the asymptomatic patient with ovarian cancer. Gynecol Oncol. 1994;55(3 Pt 2):S134–7.
2. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.
3. Covens A, Carey M, Bryson P, Verma S, Fung Kee FM, Johnston M. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol. 2002;85:71–80.
4. Vergote I, De Wever I, Tjalma W, Van Granberen M, Decloedt J, van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol. 1998;71:431–6.
5. Hou JY, Kelly MG, Yu H, et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol. 2007;105:211–7.